Research programme: vaccines - VLP Biotech

Drug Profile

Research programme: vaccines - VLP Biotech

Alternative Names: Allergy vaccine - VLP Biotech; Alzheimer's disease vaccine - VLP Biotech; Atherosclerosis vaccine - VLP Biotech; Cancer vaccine - VLP Biotech; Hepatitis B viral vaccine- VLP Biotech; Hepatitis C virus vaccine - VLP Biotech; Hypersensitivity vaccine - VLP Biotech; Influenza A virus vaccine - VLP Biotech; Lipid disorder vaccine - VLP Biotech; Malaria vaccine - VLP Biotech; Obesity vaccine - VLP Biotech; palivizumab epitope-displaying VLPs; RSV vaccine - VLP Biotech; VLP 206; VLP-162

Latest Information Update: 13 Feb 2016

Price : $50

At a glance

  • Originator ChronTech Pharma; Vaccine Research Institute of San Diego
  • Developer MedImmune; VLP Biotech
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B; Malaria; Respiratory syncytial virus infections

Highest Development Phases

  • Preclinical Hepatitis B; Malaria; Respiratory syncytial virus infections
  • Research Anthrax
  • Discontinued Alzheimer's disease; Atherosclerosis; Cancer; Hepatitis C; Hypersensitivity; Influenza virus infections; Lipid metabolism disorders; Obesity

Most Recent Events

  • 12 Feb 2016 Research programme: vaccines - VLP Biotech is available for licensing as of 12 Feb 2016.
  • 12 Feb 2016 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
  • 12 Feb 2016 Discontinued - Preclinical for Influenza virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top